JPRN-UMIN000001396已完成3 期
Randomized phase III study of FOLFOX plus bevacizumab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer - Randomized phase III study of bevacizumab containing chemotherapy for metastatic colorectal cancer
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Brain metastasis with symptoms. 2.Massive asites, pleural effusion or pericardial effusion. 3.Double cancer with in five years prior to enroll in this study. 4.Serious non-healing wound. 5.Major surgical procedure within 28 days prior to enroll in this study. 6.Minor surgical procedure within 14 days prior to enroll in this study. 7.Other serious concomitant disease. 8.Regular use of corticosteroid. 9.Regular use of anticoagulation therapy. 10.Peripheral neuropathy > Grade 1 at baseline. 11.Active infectious disease. 12.History of serious hypersensitivity. 13.Hepatitis B surface antigen. 14.Mental disorder. 15.Pregnant or nursing.
研究者
相似试验
进行中（未招募）
1 期
PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRESECTABLE pMMR AND IMMUNOSCORE IC-HIGH METASTATIC COLORECTAL CANCER PATIENTS. The AtezoTRIBE2 StudyMetastatic colorectal cancerCTIS2023-506632-32-00Gruppo Oncologico Del Nord Ovest238
已完成
2 期
Randomized phase 2 study of mFOLFOX6 plus bevacizumab versus modified OPTIMOX plus bevacizumab for metastatic colorectal cancercolorectal cancerJPRN-UMIN000003477Chiba Cancer Center Hospital80
进行中（未招募）
1 期
folfoxiri plus bevacizumab plus atezolizumab or folfoxiri plus bevacizumab nel carcinoma del colonretto metastatico.Metastatic Colorectal CancerMedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2017-000977-35-ITG.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST201
已完成
2 期
Randomized phase ll study of mFOLFOX6 + bevacizumab or mFOLFOX6+cetuximabin liver only metastasis from KRAS wild type colorectal cancerJPRN-UMIN000010209EPS Corporation120
进行中（未招募）
不适用
Randomized, Phase 2 Study of FOLFOX or FOLFIRI with AG-013736 or Bevacizumab in Patients with Metastatic Colorectal Cancer after Failure of an Irinotecan or Oxaliplatin-containing First-line RegimeSecond line treatment of patients with metastatic carcinoma of colon and rectumMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerMedDRA version: 9.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-006283-30-CZPfizer Inc, 235 East 42nd Street, New York, NY 10017, USA176